Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000122

Drug Information
CompanyGeron Corp.
IndicationBreast Cancer, Lymphoid Leukemia, Multiple Myeloma
[ICD9: 140-229, 174, 175, 203.0, 208.9   ICD10: C00-C96, C50, C90.0, C91-C95]
Phase I/II    
Solid Tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Phase I    

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESC1=CC(=CC=C1CN2C=CN=C2)C=CC(=O)O    
Isomeric SMILESC1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 868169-64-6
PubChem Compound IDCID 5282440.
Ref 1The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther. 2009 Jul;8(7):2027-35. Epub 2009 Jun 9. To Reference
Ref 2A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells. Oncogene. 2009 Feb 5;28(5):773-80. Epub 2008 Nov 10. To Reference
Ref 3Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer Res Treat. 2008 Oct 14. [Epub ahead of print] To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543